Hans Keirstead, PhD
Chairman
Bio:
Dr. Hans Keirstead is an internationally recognized expert in regenerative medicine and Chairman of Immunis, Inc., a biotechnology company with the most advanced clinical data on multi-active biologics. The company's pipeline is focused on restoring muscle function in people impacted by muscle loss due to aging, disease and/or as a result of treatments such as GLP-1s. A stem cell expert known for developing treatments for quadriplegic spinal cord injury, cancer therapies for melanoma, brain, and ovarian cancers, and a multi-pathogen vaccine, he has also advanced therapeutic research for motor neuron diseases, retinal diseases, immune disorders, and age-related immune decline. Each of Dr. Keirstead’s three prior biotechnology firms was acquired by major pharmaceutical companies for 2.5X-9.5X returns to investors, after return of investment capital.
Dr. Keirstead received his Ph.D. in neuroscience from the University of British Columbia, Canada, where he earned the Cameron Award for the country’s most outstanding dissertation. During his postdoctoral studies at the University of Cambridge, he was elected as Senate Member and became Fellow of the Governing Body of Downing College, the youngest member to do so.
In addition to his role at Immunis, Inc., Dr. Keirstead holds board positions in AIVITA Biomedical and the global Human Immunome Project.